6.21
Impella
®
System for Use During Cardiogenic Shock
Table 6.
6
Baseline patient
hemodynamics
(continued)
SAFETY AND EFFECTIVENESS RESULTS
Data for the 16 patients, who were consented for the RECOVER I study, was analyzed. The
primary endpoint (survival) was met in 88% of the cases. A Kaplan-Meier curve for survival to 1
year is provided in Figure 6.16. In addition, the implant of the Impella 5.0 and the Impella LD in
the RECOVER I was successful in all but one patient. The average support time was 3.7 ± 3 days,
with the range of support from 1.7 days to 12.6 days. The pump provided an overall average
flow during support of 3.8 ± 0.6 L/min.
Figure 6.16 Kaplan-Meier survival curve for freedom from death (to 1 year)
There were no Unanticipated Adverse Device Effects (UADEs) over the duration of the RECOVER
I trial. There were two (2) serious adverse events (SAEs) (each effecting one (1) patient), which
were adjudicated by a Medical Monitor (per protocol) as being potentially device related. One
SAE was an incidence of hemolysis, which fully resolved post-explant. A second SAE was an
incidence of sepsis or bacteremia, which was treated with antibiotics and resolved.
Measurements
RECOVER I Patients
(N=16)
[95% CI]
PA Systolic (mmHg)
Mean±SD (N)
45.3±14.8 (16)
[37.4, 53.2]
PA Diastolic (mmHg)
Mean±SD (N)
26.3±10.6 (16)
[20.7, 32.0]
Cardiac Index (l/min/m
2
)
Mean±SD (N)
1.6±0.4 (12)
[1.4, 1.9]
CVP (mmHg)
Mean±SD (N)
13.9±6.1 (15)
[10.5, 17.2]
Number of Inotropes
Mean±SD (N)
1.56±0.63 (16)
[1.23, 1.90]
Number of Pressors
Mean±SD (N)
0.40±0.63 (15)
[0.05, 0.75]
6
C
LIN
IC
A
L E
X
P
E
RI
E
N
C
E
Summary of Contents for Impella 2.5
Page 4: ......
Page 8: ......
Page 10: ......
Page 12: ......
Page 15: ...2 WARNINGS AND CAUTIONS WARNINGS 2 1 CAUTIONS 2 3...
Page 16: ......
Page 22: ......
Page 38: ......
Page 40: ......
Page 108: ......
Page 171: ......
Page 173: ......
Page 181: ......
Page 183: ......
Page 201: ......
Page 203: ......
Page 205: ......
Page 210: ...INDEX TBD...